TibaRay has launched a Regulation CF investment campaign on Wefunder, making the company accessible to individual investors as it advances its next-generation accelerator technology designed for FLASH radiotherapy. This development matters because FLASH radiotherapy represents a potential paradigm shift in cancer treatment, with research suggesting ultrafast radiation delivery could significantly reduce damage to healthy tissue while maintaining effectiveness against tumors.
The company's mission focuses on curing cancer "in a FLASH" by enabling radiation delivery hundreds of times faster than current systems. Enabling this treatment requires fundamentally new accelerator technology, which TibaRay is developing as a Stanford spinout built on decades of accelerator physics and medical physics research. More than $27 million has already been invested in the technology's development, including over $14 million in non-dilutive federal research grants.
TibaRay's intellectual property portfolio includes more than 20 issued and pending patents related to next-generation radiotherapy systems. The company's proprietary Galactica linear accelerator has already been integrated into Leo Cancer Care's upright radiotherapy system, marking TibaRay's first commercial accelerator platform integration. This demonstrates early validation of the technology within the medical industry.
The company is pursuing a phased commercialization strategy with near-term revenue generation from commercializing accelerator technology across medical and adjacent markets including imaging, security scanning, and non-destructive testing. The long-term objective involves deployment of the PHASER radiotherapy system specifically designed to enable ultrafast treatment delivery. The Wefunder campaign allows individual investors to participate in this next development phase as the company works toward making FLASH radiotherapy clinically available.
Investors can review the full opportunity, including technology details, partnerships, and development plans on the TibaRay campaign page. The advancement of FLASH radiotherapy technology could have significant implications for cancer patients worldwide by potentially reducing treatment side effects and improving quality of life during radiation therapy. As research continues to validate the FLASH approach, companies like TibaRay are working to translate laboratory findings into clinical reality through technological innovation.
